Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFN -Associated Mood Disorders
|
|
- Aron Stokes
- 6 years ago
- Views:
Transcription
1 Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFN -Associated Mood Disorders MARTIN SCHAEFER, M.D., JOCHEN WINTERER, M.D. RAHUL SARKAR, M.D, RALF UEBELHACK, M.D. LEONORA FRANKE, M.D., ANDREAS HEINZ, M.D. ASTRID FRIEBE, M.D. Background: Interferon-alpha (IFN )-associated mood disorder is a major complication of treatment for chronic hepatitis C. Method: The authors report on three patients infected with chronic hepatitis C showing severe depressive symptoms during or after IFN treatment. Because patients had lowered tryptophan blood levels and did not response to antidepressants, they received tryptophan up to a dosage of 1,000 mg/day as mono- or add-on treatment. Results: Tryptophan, used as augmentation or monotherapeutic treatment, led to a significant improvement of depressive symptoms in all three patients. Conclusion: A tryptophan deficit seems to be involved in the pathophysiology of persistent mood changes during and after IFN treatment. (Psychosomatics 2008; 49: ) Worldwide, 170 million people are estimated to be chronically infected with the hepatitis C virus (HCV). For patients with an HCV infection, an increased incidence of psychiatric symptoms have been described, especially symptoms of fatigue, mental tiredness, poor concentration, forgetfulness, depression, irritability, and sleeping problems. 1 Several pathophysiological mechanisms have been discussed, including changes in central dopamine and serotonin transporters, 2 as well as virus brain interactions. 3,4 Moreover, chronic infectious diseases have been shown to be associated with peripheral changes of the Received March 26, 2007; revised July 13, 2007; accepted August 1, From the Dept. of Psychiatry and Psychotherapy, Charité Universitätsmedizin, Berlin, Germany and the Dept. of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, Essen, Germany. Send correspondence and reprint requests to Martin Schaefer, M.D., Dept. of Psychiatry, Psychotherapy, and Addiction Medicine, Kliniken Essen-Mitte, Henricistr, 92, D Essen, Germany. martin. schaefer@charite.de 2008 The Academy of Psychosomatic Medicine serotonergic system, especially with decreased tryptophan concentrations and an increased kynurenin/tryptophan ratio. 5 So far, interferon-alpha (IFN ) is the only effective immunotherapeutic agent for the treatment of viral hepatitis. However, clinical use of IFN is often complicated by psychiatric side effects. 6 Sleep disturbance, fatigue, irritability, mania, anhedonia, depression, cognitive disturbances, and even suicidal thoughts or suicide attempts have been observed during treatment with IFN. The most important psychiatric side effect of IFN is the induction of episodes of major depression, which has been reported to occur in 30% 50% of patients. Depression and fatigue are thought to be associated with changes in serotonergic neurotransmission and metabolism. 6 Besides an increase of serotonin transporters and a decrease of postsynaptic serotonin receptors, reduced tryptophan availability has been reported during hepatitis C infection and IFN treatment IFN activates the enzyme indoleamine-2,3-dioxygenase (IDO), which catalyzes the rate-limiting step of peripheral tryptophan conversion into kynurenine and Psychosomatics 49:5, September-October 2008
2 Schaefer et al. quinolinic acid. Because tryptophan is the essential precursor of central serotonin (5-HT) production, this effect might contribute to a central serotonin deficit. Low tryptophan levels have been shown to be associated with symptoms of depression. 11 It has been postulated that about 25% of chronic HCVinfected patients and 30% of IFN -treated patients need antidepressant treatment. 1 Regarding IFN -associated mood changes, several case reports and case series demonstrated a positive effect of antidepressants, especially selective serotonin-reuptake inhibitors (SSRIs) So far, three prospective trials have provided evidence that preemptive antidepressant therapy with SSRIs can significantly reduce the incidence and severity of depression during IFN treatment However, although the response rate of HCV- and IFN-associated depression to antidepressant treatment seems to be very high, most of the patients do not show a complete remission of depression symptoms, sleeping disturbances, anxiety, or fatigue. This might be due to the fact that reuptake-inhibition of serotonin does not fully compensate for the hypothesized serotonergic deficit during chronic HCV-infection and IFN treatment. Thus, reduced tryptophan availability might be an additional important factor explaining HCV- or IFN-associated mental changes. We therefore hypothesized that tryptophan as augmentation strategy or as monotherapy may have its own specific antidepressant effect in patients with depression during chronic hepatitis C infection or during/after antiviral treatment with IFN by increasing the availability of tryptophan for conversion into 5-HT. In the following article, we report on three cases in which tryptophan treatment resulted in a significant improvement of IFN -induced depression symptoms during and after IFN treatment of chronic hepatitis C infection. Case Reports Case 1 A 42-year-old company employee ( Mr. A ) was treated with pegylated IFN and ribavirin because of a chronic hepatitis C infection (genotype 1). After 4 months, he developed depressive mood changes accompanied by anxiety, diminished activity and self-confidence, social withdrawal, and suicidal thoughts. Treatment efforts with mirtazapine (up to 60 mg/day), lithium (1,150 mg/day), and valproic acid (1,000 mg/day) led to only a slight improvement, but not a remission of symptoms. Because depressive symptoms worsened (suicidal thoughts, sleeping disturbances, and agitation occurred), IFN treatment had to be stopped. Nevertheless, psychiatric symptoms did not improve spontaneously during the next 6 weeks, and the patient was admitted to our psychiatric ward with a Hamilton Rating Scale for Depression (Ham D) score of 23. During the next 4 weeks, we changed antidepressant treatment to a dosage of up to 40 mg/day of citalopram. The patient complained about an increase in agitation and sleeplessness, without a significant improvement in depressive symptoms. At this time, he even attempted suicide. Because of the strong agitation, citalopram was reduced to 20 mg/day, and amisulpirid was administered to the patient over the course of 2 weeks (200 mg 400 mg/day). This resulted in only a slight improvement in anxiety and agitation symptoms. Measurement of plasma tryptophan at this time showed a significant lowering (8.8 lg/ml; normal range: 11.0 lg/ml 15.0 lg/ ml). We therefore started augmentation treatment with L- tryptophan up to 1,000 mg in the evening. During the next 3 weeks, Mr. A showed rapid and significant improvement, with a decrease in depression symptoms and also a normalization of sleep, followed by a reduction of his agitation (Figure 1). With only 20 mg citalopram/day and L-tryptophan 1,000 mg/day, his Ham D score significantly dropped to normal range (a score of 6), reflecting a significant stabilization of his affective status. FIGURE 1. Serum Tryptophan (µg/ml) Ham D Scores and Tryptophan Serum Levels for Patient #1 After Starting Tryptophan-Augmentation Treatment (1,000 mg/day) Ham D Day 0 Day 7 Day 14 Day 21 Days of Treatment Tryptophan (11 15µg/ml) Ham D: Hamilton Rating Scale for Depression; normal tryptophan serum levels: 11 lg/ml 15 lg/ml. Psychosomatics 49:5, September-October
3 Case Reports Case 2 A 50-year-old woman ( Ms. B ), who had been infected with HCV (genotype 1) for 25 years, was initially treated with standard IFN and ribavirin in She developed psychiatric side effects including fatigue, severe depression, and difficulties in concentration and memory. After 3 months, she had to discontinue treatment because of suicidal thoughts. During the following years, the patient complained about recurrent or even persistent psychiatric symptoms such as fatigue and depression. Because of the increased fibrosis diagnosed by liver histology in 2003, a hepatologist and the patient decided to start a new antiviral combination treatment with peg- IFN and ribavirin. Before the treatment, the patient was seen in our psychiatric outpatient clinic and received antidepressant treatment with citalopram 20 mg/day for the first time. While being treated, most of her depression symptoms disappeared. Three months later, the patient was able to start antiviral treatment with peg-ifn -2a and ribavirin. During the first 4 weeks, she developed flu-like symptoms, sleeping disturbance, and fatigue, but no depressive symptoms. Zopiclon was added to the antidepressant treatment to improve sleep. In the second treatment month, depression scores significantly increased, and citalopram was increased to 40 mg/day. Nevertheless, the patient complained about a worsening of fatigue and depressive symptoms such as anhedonia, spontaneous crying, ruminative thinking, feelings of desperation, and hopelessness, combined with difficulties in concentration and memory. Add-on treatment with mirtazapine (30 mg/day) was started, but depression scores and symptoms did not improve during the next 3 weeks. Because her HCV PCR was negative, suggesting that she was a responder, the patient and the hepatologist decided to continue the antiviral treatment without any reduction in dosage. We measured tryptophan plasma concentration, which was low (7.5 lg/ml; normal range for women: 9.5 lg/ml 13.9 lg/ml). With the patient s informed consent, mirtazapine was stopped, and tryptophan was started, with 1,000 mg in the evening as add-on medication to the continuous treatment with citalopram 40 mg/ day. In the next days, the patient complained about hyperactivity, agitation, and sleeplessness, although other symptoms, such as fatigue, depressive mood changes, lack of motivation, and reduced psychomotor activity improved. At this time, tryptophan plasma concentration was significantly increased (to 21 lg/ml). Citalopram was reduced to 20 mg per day, and tryptophan to 500 mg for several days, and than again increased to 1,000 mg/day. During the next 3 weeks, depression scores decreased significantly. Ms. B also reported a significant improvement in fatigue and a slight improvement in concentration and memory, respectively. With a combined treatment of 20 mg citalopram/day and 500 mg tryptophan/day, the patient was able to continue antiviral treatment without the need to reduce the dosage of antiviral treatment with peg-ifn -2a and ribavirin. Case 3 A 61-year-old woman ( Ms. C ) had a chronic HCV (genotype 1) infection after having worked in a medical laboratory in the 1980s. Antiviral treatment with IFN was started in 2000, but had to be stopped after 3 months without clearance of HCV because of severe depressive symptoms, including suicidal ideation, inactivity, psychomotor slowing, and severe fatigue. However, even after antiviral treatment was discontinued, she complained about a persistent lack of motivation, inactivity, chronic fatigue, and repeated episodes of depressed mood over the next 2 years, significantly affecting her quality of life and ability to work. In 2003, she came to our psychiatric outpatient department. Her Montgomery-Asberg Depression Rating Scale (MADRS) score was 19, and serum levels of tryptophan were significantly reduced (at 6.6 lg/ml; normal range: 9.5 lg/ml 13.9 lg/ml). Ms. C refused treatment with antidepressants because of her lack of response to paroxetine treatment, with persistent side effects, 2 years earlier. With her informed consent, we started tryptophan 1,000 mg/day as monotherapy. Serum tryptophan levels continually increased over the next 6 weeks, while MADRS scores decreased over the same period of time, to a total score of 9. Over the next 6 months, the patient reported an ongoing and significant improvement of mood, a reduction of fatigue, and an increase in daily activities. Discussion Our cases reflect three different types of HCV- and IFN - associated problems: depression during antiviral treatment, depression persisting over weeks or months after termination of IFN treatment, and long-term psychiatric problems in patients with chronic HCV infection who had been treated with IFN without success and who developed severe psychiatric side effects. None of the patients presented Psychosomatics 49:5, September-October 2008
4 Schaefer et al. here had a preexisting psychiatric disorder, especially depression, independent from chronic hepatitis C infection or cytokine treatment. Psychiatric symptoms developed during the treatment with standard or pegylated interferons and, interestingly, did not disappear after discontinuation of antiviral therapy for all three of these patients. Although, so far, no long-term data from large, prospective, controlled trials are available, several case reports have recently been presented reporting on ongoing psychiatric problems lasting several months after IFN treatment for chronic hepatitis C had been terminated Proinflammatory cytokines and an increased consumption of tryptophan via activation of IDO are currently discussed as an important part of the pathophysiological model of depressive states during inflammatory somatic disorders. 29 In our patients with persistent mood changes, significantly lowered tryptophan blood levels were measured several weeks or even months after IFN treatment had been terminated. Normalization of serum levels during tryptophan treatment was associated with an improvement of depressive symptoms in these patients. Our cases support the view that psychiatric or psychosomatic symptoms during or after IFN treatment in HCV-infected patients might also be associated with a tryptophan deficit. In all three patients, tryptophan augmentation or monotherapy was a useful and effective pharmacotherapeutic strategy to reduce psychiatric symptoms after only partial response to antidepressants. Moreover, patients also reported a significant improvement in fatigue, psychomotor slowing, lack of motivation, and inactivity. A lowered availability of plasma tryptophan has been shown in patients with chronic infectious diseases, sleeping disturbances, and depression. 5,30 As a consequence, reduced tryptophan levels in our patients might be associated with both chronic HCV infection and the cytokine treatment with IFN. Preexisting changes in tryptophan or serotonergic homeostasis cannot be excluded because of the lack of pretreatment blood samples. However, the observation that mood changes in all patients occurred only during or after interferon treatment rather indicates a direct involvement of cytokine treatment with IFN in metabolic changes of the tryptophan pathway. In one patient, tryptophan treatment was followed by agitation, irritability, and insomnia. This was probably part of a beginning serotonergic syndrome, which disappeared after citalopram and tryptophan were reduced. Although our patient did not develop a full serotonergic syndrome including clonus, diarrhea, diaphoresis, or rigidity, the risk of a serotonergic syndrome due to increased central 5-HT concentrations has to be considered, and patients should be carefully monitored. Also, a mixed mood state could be possible, but these patients had no history of bipolar symptoms and did not demonstrate bipolar mood changes in the following months. However, in addition to the acute positive effects on IFN -induced mood changes demonstrated in our cases, tryptophan and its metabolism are also believed to be involved in long-term changes such as depression or cognitive disturbances in patients with chronic hepatitis C during or after IFN treatment. IFN activates the enzyme IDO; therefore, tryptophan augmentation during IFN treatment may lead to an increased production of quinolinic acid. 11,31 Quinolinic acid is a potent neurotoxin with an additional and marked free-radical producing property. There are a number of inflammatory and neurodegenerative disorders whose pathogenesis has been demonstrated to involve multiple imbalances of kynurenine-pathway metabolism (multiple sclerosis, Parkinson s, Alzheimer s, and Huntington s diseases). 32 All in all, our case reports are the first to indicate a significant therapeutic benefit of tryptophan augmentation in patients with IFN -associated depression. This seems to be especially successful in patients with non-response or only partial response to antidepressants. However, more clinical data are needed to understand the long-term mood and cognitive changes during or after IFN treatment in patients with chronic hepatitis C in order to develop effective therapeutic strategies. References 1. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon : a review. Am J Psychiatry 2000; 157: Weissenborn K, Berding G, Kostler H: Altered striatal dopamine D 2 receptor density and dopamine transport in a patient with hepatic encephalopathy. Metab Brain Dis 2000; 15: Forton DM, Taylor-Robinson SD, Thomas HC: Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: Weissenborn K, Krause J, Bokemeyer M, et al: Hepatitis C virus infection affects the brain: evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: Fuchs D, Moller AA, Reibnegger G, et al: Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in HIV type 1 infection. Immunol Lett 1991; 28: Schaefer M, Engelbrecht MA, Gut O, et al: Interferon alpha (IFN ) Psychosomatics 49:5, September-October
5 Case Reports and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: Abe S, Hori T, Suzuki T, et al: Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999; 24: Asnis GM, De La Garza R II: Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006; 40: Bonaccorso S, Marino V, Puzella A, et al: Increased depressive ratings in patients with hepatitis C receiving interferon -based immunotherapy are related to interferon -induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: Cai W, Khaoustov VI, Xie Q, et al: Interferon -induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005; 42: Capuron L, Neurauter G, Musselman DL, et al: Interferon -induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: Licinio J, Kling MA, Hauser P: Cytokines and brain function: relevance to interferon -induced mood and cognitive changes. Semin Oncol 1998; 25: Maes M, Meltzer HY, Scharpe S, et al: Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993; 49: Schaefer M, Schwaiger M, Pich M, et al: Neurotransmitter changes by interferon and therapeutic implications. Pharmacopsychiatry 2003; 36(Suppl 3):S203 S Tsao CW, Lin YS, Cheng JT, et al: Serotonin transporter mrna expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol 2006; 63: Hauser P, Khosla J, Aurora H, et al: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: Kraus MR, Schafer A, Faller H, et al: Paroxetine for the treatment of interferon -induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: Kraus MR, Schafer A, Scheurlen M: Paroxetine for the prevention of depression induced by interferon. N Engl J Med 2001; 345: Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon. Am J Gastroenterol 1993; 88: Schafer M, Schmidt F, Amann B, et al: Adding low-dose antidepressants to interferon treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42(Suppl 1): Schramm TM, Lawford BR, Macdonald GA, et al: Sertraline treatment of interferon -induced depressive disorder. Med J Aust 2000; 173: Valentine AD, Meyers CA: Successful treatment of interferon - induced mood disorder with nortriptyline. Psychosomatics 1995; 36: Kraus MR, Schafer A, Al Taie O, et al: Prophylactic SSRI during interferon re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon.n Engl J Med 2001; 344: Schaefer M, Schwaiger M, Garkisch AS, et al: Prevention of interferon -associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: Gohier B, Goeb JL, Rannou-Dubas K, et al: Hepatitis C, alpha interferon, anxiety, and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003; 4: Nickel T, Sonntag A, Backmund M, et al: Depression during therapy with interferon : how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38: Rifflet H, Vuillemin E, Oberti F, et al: [Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon ]. Gastroenterol Clin Biol 1998; 22: Muller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: toward an integrated view of depression. Mol Psychiatry 2007; 12: Song C, Lin A, Bonaccorso S, et al: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998; 49: Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses 2005; 65: Sas K, Robotka H, Toldi J, et al: Mitochondria, metabolic disturbances, oxidative stress, and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007; 257: Psychosomatics 49:5, September-October 2008
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C *
Journal of Hepatology 42 (2005) 793 798 www.elsevier.com/locate/jhep Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C * Martin Schaefer 1, *, Markus
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Hepatitis C- Associated Depression Ondria C. Gleason, MD, FAPA, FAPM University of Oklahoma School of Community Medicine Tulsa, OK Ondria
More informationManagement of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction
SUPPLEMENT ARTICLE Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction Martin Schaefer, 1,2 Rahul Sarkar, 3 and Crisanto Diez-Quevedo
More informationDepression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment
REVIEW Annals of Gastroenterology (2015) 28, 440-447 Depression and suicide in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment Laura A. Lucaciu,
More informationPsychiatric Guidelines for Hepatitis C Treatment (Interferon-based) Introduction
Psychiatric Guidelines for Hepatitis C Treatment (Interferon-based) Introduction There is an increased prevalence of psychiatric co-morbidity in patients with chronic HCV infection Antiviral combination
More informationDepressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C
Antiviral Therapy 9:905 909 Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C Montserrat Laguno 1 *, Jordi Blanch 2,
More informationManaging the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C CATHERINE C. CRONE, MD; GEOFFREY M. GABRIEL, MD; AND THOMAS N. WISE, MD ABSTRACT Neuropsychiatric side effects are
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationComparison of the latency time of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors
Journal of Medicine and Medical Science Vol. 2(9) pp. 1085-1092, September 2011 Available online@ http://www.interesjournals.org/jmms Copyright 2011 International Research Journals Full Length Research
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationAddressing Psychiatric Issues Prior to HCV Treatment. Glenn J. Treisman, MD, PhD The Johns Hopkins University School of Medicine Baltimore, Maryland
Addressing Psychiatric Issues Prior to HCV Treatment Glenn J. Treisman, MD, PhD The Johns Hopkins University School of Medicine Baltimore, Maryland Disclosure Information Dr Treisman has not relevant financial
More informationPsychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review
Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review ROSA QUELHAS, MD ALICE LOPES, MD Objective. Neuropsychiatric symptoms are
More informationPsychiatric Manifestations of Celiac Disease
Psychiatric Manifestations of Celiac Disease Venkatesh Handratta MS, MD Assistant Professor Department of Psychiatry Medstar Georgetown University Hospital OBJECTIVES The objective of this talk is for
More informationDepression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:
Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now
More informationAffective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018
Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationBiology 3201 Nervous System # 7: Nervous System Disorders
Biology 3201 Nervous System # 7: Nervous System Disorders Alzheimer's Disease first identified by German physician, Alois Alzheimer, in 1906 most common neurodegenerative disease two thirds of cases of
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationAntidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School
Antidepressants and Sedatives David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School Depression A frequent problem, affecting up to 5% of the population Common presentations
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationPrevalence and Risk Factors of Depression and Anxiety in Hepatitis C Patients Receiving Pegylated Interferon Alpha (IFN-a)
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 484-493 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.059
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationThe current standard-of-care for patients with
Evaluation of Depression as a Risk Factor for Treatment Failure in Chronic Hepatitis C Peter Derek Christian Leutscher, 1 Martin Lagging, 2 Mads Rauning Buhl, 1 Court Pedersen, 3 Gunnar Norkrans, 2 Nina
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationTherapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationStudie 083 (950E-CNS )
Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationJoyce Seiko Kobayashi, MD S E C T I O N. Introduction
c h a p t e r Mental Health and Hepatitis C 21 Joyce Seiko Kobayashi, MD S E C T I O N 2 Mental Health Issues During Interferon-Based Therapy Introduction Most people are aware that the significant benefits
More informationPSYCH 235 Introduction to Abnormal Psychology. Agenda/Overview. Mood Disorders. Chapter 11 Mood/Bipolar and Related disorders & Suicide
PSYCH 235 Introduction to Abnormal Psychology Chapter 11 Mood/Bipolar and Related disorders & Suicide 1 Agenda/Overview Mood disorders Major depression Persistent Depressive Disorder (Dysthymia) Bipolar
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationAre All Older Adults Depressed? Common Mental Health Disorders in Older Adults
Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Cherie Simpson, PhD, APRN, CNS-BC Myth vs Fact All old people get depressed. Depression in late life is more enduring and
More informationJoel V. Oberstar, M.D. 1
Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationThe Nervous System Mark Stanford, Ph.D.
The Nervous System Functional Neuroanatomy and How Neurons Communicate Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Addiction Medicine and Therapy Services The Nervous System In response
More informationPOLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital
POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 212 PSYCHOPHARMACOLOGY SERIES Guna Kanniah Waikato Hospital POLYPHARMACY FIVE REASONS FOR POLYPHARMACY 1. To treat a concomitant disorder 2. To treat an
More informationMichael Berk 1,2,3, Seetal Dodd 1, Olivia M Dean 1,3, Kristy Kohlmann 1, Lesley Berk 1,4,GinSMalhi 5,6
Acta Neuropsychiatrica 2010: 22: 237 242 All rights reserved DOI: 10.1111/j.1601-5215.2010.00472.x 2010 John Wiley & Sons A/S ACTA NEUROPSYCHIATRICA The validity and internal structure of the Bipolar Depression
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationThe Neurobiology of Mood Disorders
The Neurobiology of Mood Disorders J. John Mann, MD Professor of Psychiatry and Radiology Columbia University Chief, Department of Neuroscience, New York State Psychiatric Institute Mood Disorders are
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationDepression Workshop 26 January 2007
Depression Workshop 26 January 2007 Leslie G Walker Professor of Cancer Rehabilitation Donald M Sharp Senior Lecturer in Behavioural Oncology Mary B Walker Senior Clinical and Research Nurse Specialist
More informationA Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
More informationHepatitis C virus (HCV) infection is the most frequent. Original Research
Original Research Annals of Internal Medicine Escitalopram for the Prevention of Peginterferon- 2a Associated Depression in Hepatitis C Virus Infected Patients Without Previous Psychiatric Disease A Randomized
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationBIOLOGICAL TREATMENT IN PSYCHIATRY. PTE ÁOK Dept.of Psychiatry Pécs
BIOLOGICAL TREATMENT IN PSYCHIATRY PTE ÁOK Dept.of Psychiatry Pécs 1 SGA effects pharmacokinetic effect chemical strucrure Receptor block D2 5-HT2 α1 H-1 M Selectíve DA (D2D3) antagonists Benzamids Amisulpiride
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More informationDEPRESSION. Dr. Jonathan Haverkampf, M.D.
Dr., M.D. Depression is one of the most common medical conditions, which can interfere with a person s quality of life, relationships and ability to work significantly. Fortunately, there are a number
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationThe Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (1), Page
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (1), Page 5743-5747 Impact of Direct Acting Antiviral Drugs (DAADs) on Cognitive function among Hepatitis C Virus Infected Patients Hassan
More informationCurriculum Vitae, Michael J. Downing, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com PROFESSIONAL AFFILIATIONS: Michael
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abuse alcohol, aggression and, 52 53 substance, aggression and, 52 54 ACE. See Aid to Capacity Evaluation (ACE). AEDs. See Antiepileptic
More informationESCITALOPRAM. THERAPEUTICS Brands Lexapro see index for additional brand names. Generic? Yes
ESCITALOPRAM THERAPEUTICS Brands Lexapro see index for additional brand names Generic? Yes Class SSRI (selective serotonin reuptake inhibitor); often classified as an antidepressant, but it is not just
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationPHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS
PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS Yogesh Dwivedi, Ph.D. Assistant Professor of Psychiatry and Pharmacology Psychiatric Institute Department of Psychiatry
More informationPsychological side-effects of immunotherapies in the treatment of malignant melanoma
Psychological side-effects of immunotherapies in the treatment of malignant melanoma Ph.D. Theses Kovács Péter School of Ph.D. Studies, Semmelweis University School of Mental Health Sciences Supervisor:
More informationSubstance and Medication Induced Mood Disorders KELLY GODECKE, MD PSYCHIATRY DEPARTMENT UNIVERSITY OF UTAH
Substance and Medication Induced Mood Disorders KELLY GODECKE, MD PSYCHIATRY DEPARTMENT UNIVERSITY OF UTAH Substance Induced Depressive Disorder A. A prominent and persistent disturbance in mood that predominates
More informationDepressive, Bipolar and Related Disorders
Depressive, Bipolar and Related Disorders Robert Kelly, MD Assistant Professor of Psychiatry Weill Cornell Medical College White Plains, New York Lecture available at www.robertkelly.us Financial Conflicts
More informationDiabetes. & Mental Health. David J. Robinson MD, FRCPC. This slide is for review purposes only and not for presentations.
Diabetes This slide is for review purposes only and not for presentations & Mental Health David J. Robinson MD, FRCPC CMHA - London, ON In the past 2 years, I have received speaking honoraria from, and
More informationHDSA welcomes you to Caregiver s Corner. Funded by an educational grant from
HDSA welcomes you to Caregiver s Corner Funded by an educational grant from Caregiver s Corner Webinar, DATE Managing Psychiatric Symptoms Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics
More informationThe Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder
Duquesne University Duquesne Scholarship Collection Graduate Student Research Symposium The 4th Annual Graduate Student Research Symposium September 19, 2017 The Safety and Efficacy of Ondansetron in the
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationDidactic Series. Depression in HIV/AIDS
Didactic Series Depression in HIV/AIDS Lawrence M. Mc Glynn MD Clinical Associate Professor Stanford University School of Medicine San Jose AETC July 11, 2013 ACCREDITATION STATEMENT: University of California,
More informationA new Anatomy of Melancholy: rethinking depression and resilience
A new Anatomy of Melancholy: rethinking depression and resilience Prof Declan McLoughlin Dept of Psychiatry & Trinity College Institute of Neuroscience Trinity College Dublin St Patrick s University Hospital
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationDepressive and Bipolar Disorders
Depressive and Bipolar Disorders Symptoms Associated with Depressive and Bipolar Disorders Characteristics of mood symptoms Affects a person s well being, school, work, or social functioning Continues
More informationManagement of a HIV-infected patient with a psychiatric disorder
Management of a HIV-infected patient with a psychiatric disorder Maria Ferrara, Modena, Italia Guida Da Ponte, Lisboa, Portugal Jordi Blanch, Barcelona Main complaint Mr M is a 30-year-old HIV+ man In
More informationClozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders
Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationThe Link Between Depression and Physical Symptoms
The Link Between Depression and Physical Symptoms Madhukar H. Trivedi, M.D. Physical symptoms are common in depression, and, in fact, vague aches and pain are often the presenting symptoms of depression.
More informationQUEPINE XR PRODUCT INFORMATION. Name of the medicine. Description. Pharmacology
QUEPINE XR PRODUCT INFORMATION Name of the medicine Quetiapine fumarate. The chemical name is Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin- 1-yl] ethoxy) ethanol] fumarate. Its structural formula
More informationPharmacologic Treatment of Acute Major Depression and Dysthymia
POSITION PAPERS CLINICAL GUIDELINE, PART 1 Pharmacologic Treatment of Acute Major Depression and Dysthymia Vincenza Snow, MD; Steven Lascher, DVM, MPH; and Christel Mottur-Pilson, PhD, for the American
More informationHDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.
HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics University of Iowa, Iowa City, Iowa The information provided
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationOrganic Acids Part VII Dr. Jeff Moss
Using organic acids to resolve chief complaints and improve quality of life in chronically ill patients Part VII Jeffrey Moss, DDS, CNS, DACBN jeffmoss@mossnutrition.com 413-530-08580858 (cell) 1 Tryptophan
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationPOST STROKE DEPRESSION. Dr. Maria Hussain, MD FRCPC Geriatric Psychiatrist Assistant Professor Department of Psychiatry Queen s University
POST STROKE DEPRESSION Dr. Maria Hussain, MD FRCPC Geriatric Psychiatrist Assistant Professor Department of Psychiatry Queen s University DISCLOSURES No conflict of interest OBJECTIVES Review the epidemiology
More informationThe Context: Why is this so important to treat?
Depression for PG1s Ian A. Cook, M.D. UCLA Department of Psychiatry Laboratory of Brain, Behavior, and Pharmacology Semel Institute for Neuroscience & Human Behavior DepressionLA.com PsychiatryGuidelines.com
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More informationDepression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives
DISCLOSURES Depression & Suicide July 19, 2017 GenaLynne C. Mooneyham, MD, MS Pediatrics/Psychiatry/Child & Adolescent Psychiatry No financial disclosures There may be discussion of off label medication
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationDepression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders
Clinical report Eur J Dermatol 2009; 19 (6): 611-5 Ricard NAVINÉS 1,2 Esther GÓMEZ-GIL 2 Susana PUIG 3 Inmaculada BAEZA 4,5 Joan DE PABLO 2 Rocío MARTÍN-SANTOS 1,2,5 1 Unitat de Recerca Farmacològica (URF),
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More information